[Minutes, Advisory Committee to the Director GP-160 Meeting (1992: Bethesda, Maryland)]

1 that if these proven infected children had their
2 disease course slowed following immunization, then
3 rather than having a clinical endpoint, as we would
4 have in adult trials, which is at a great distance in
5 time from immunization, the entire program could be
6 brought much closer together. We might get clinical
7 endpoints earlier. I just want to throw that thought
8 and observation open to you.
9 Secondly, prevention of perinatal HIV
10 transmission obviously is a goal for us in pediatrics
11 -- it's one of our major goals -- by immunizing either
12 HIV-infected pregnant women and looking at whether we
13 can decrease the transmission to their offspring or,
14 I believe preferably, in the hepatitis b model
15 immunizing all offspring born to HIV-infected women to
16 see if we can decrease the transmission.
17 I think we can answer the transmission
18 questions quite quickly, much more quickly and using
19 far fewer patients than would be required were we to
20 approach the adult population.
21 I have to remind you that there's a good
22 deal of debate, and I think many individuals around
NEAL R. GROSS
COURT REPORTERS AND TRANSCRISERS
1323 RHODE ISLAND AVENUE, N.W.
[phone] WASHINGTON. D.C. 20005 [phone]